26 / 42
CheckMate 227: PFS en pacientes con alta TMB en función de PD-L1
26
≥1% PD-L1
<1% PD-L1
38
20
16
15
10
8
4
1
0
48
30
16
4
1
1
1
0
0
Nivo + ipi
(n = 38)
QT
(n = 48)
Mediana PFS, mo
b
7.7
5.3
HR
95% CI
0.48
0.27, 0.85
QT
Nivolumab +
ipilimumab
Months
0
20
40
60
80
100
0
6
12
18
3
9
15
21
24
1-y PFS = 45%
1-y PFS = 8%
101
65
50
40
26
16
7
2
0
112
73
35
13
6
5
3
0
0
1-y PFS = 42%
1-y PFS = 16%
PFS (%)
QT
Nivolumab +
ipilimumab
Months
0
20
40
60
80
100
0
6
12
18
3
9
15
21
24
Nivo + ipi
(n = 101)
QT
(n = 112)
Mediana PFS, mo
a
7.1
5.5
HR
95% CI
0.62
0.44, 0.88
Nivo + ipi
No. at risk
Chemo
a
95% CI: nivo + ipi (5.5, 13.5 mo), chemo (4.3, 6.6 mo);
b
95% CI: nivo + ipi (2.7 mo, NR), chemo (4.0, 6.8 mo)
Borghaei H et al, ASCO 2018